Exchange Announcement • 12 Oct 2026 21:01
Announcement On Behalf Of Pharmaessentia Singapore Pte. Ltd.: Filing For An Additional Indication Of Besremi For Et In Singapore
Exchange Announcement • 18 Sep 2026 05:37
Announcement Of Positive Dsmb Recommendation To Continue Phase Iii P1101 Trial For Pre-Fibrotic/Early Pmf Or Overt Pmf At Low Or Intermediate-1 Risk
Exchange Announcement • 04 Sep 2026 19:38
The Company To Attend Wells Fargo’S Investor Conference “21st Annual Healthcare Conference.”
Exchange Announcement • 29 Aug 2026 08:26
U.S. Fda Has Approved Besremi (Ropeginterferon Alfa-2b-Njft) For Adults With Essential Thrombocythemia (Et)
Exchange Announcement • 24 Aug 2026 14:40